Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBAY 707 is a potent and selective MTH1 inhibitor (IC50 = 2.3 nM); exhibits no significant activity at 1 μM concentration against a panel of 97 kinases. BAY 707 is cell-permeable and active in vivo, and displays no antitumor activity in vitro or in vivo.
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the BAY-707 probe summary on the SGC website.
Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of BAY 707 is reviewed on the chemical probes website.
M. Wt | 288.34 |
Formula | C15H20N4O2 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 2109805-96-9 |
PubChem ID | 129012086 |
InChI Key | RPMGXDCRCWWCRY-JTQLQIEISA-N |
Smiles | CCNC(C1=CC2=C(N3CCOC[C@@H]3C)C=CN=C2N1)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 28.83 | 100 | |
ethanol | 2.88 | 10 |
The following data is based on the product molecular weight 288.34. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.47 mL | 17.34 mL | 34.68 mL |
5 mM | 0.69 mL | 3.47 mL | 6.94 mL |
10 mM | 0.35 mL | 1.73 mL | 3.47 mL |
50 mM | 0.07 mL | 0.35 mL | 0.69 mL |
References are publications that support the biological activity of the product.
Rahm et al (2018) Creation of a novel class of potent and selective MutT Homologue 1 (MTH1) inhibitors using fragment-based screening and structure-based drug design. J.Med.Chem. 61 2533 PMID: 29485874
Ellermann et al (2017) Novel class of potent and cellularly active inhibitors devalidates MTH1 as broad-spectrum cancer target. ACS Chem.Biol. 12 1986 PMID: 28679043
If you know of a relevant reference for BAY 707, please let us know.
Keywords: BAY 707, BAY 707 supplier, BAY707, SGC, Nudix, hydrolase, 1, NUDT1, MutT, Homolog1, MTH1, inhibitor, inhibitors, inhibits, potent, selective, cell, permeable, active, in, vivo, homolog-1, (MTH1), 6562, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for BAY 707. Do you know of a great paper that uses BAY 707 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review BAY 707 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.